Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer-Reference-Cited by-同舟云学术

Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer

Published:2021-09-09 Issue:18 Volume:64 Page:13410-13428
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Aicher Thomas D.¹^ORCID,Van Huis Chad A.¹,Hurd Alexander R.¹,Skalitzky Donald J.¹,Taylor Clarke B.¹,Beleh Omar M.¹^ORCID,Glick Gary²,Toogood Peter L.¹,Yang Bing³,Zheng Tao³,Huo Changxin³,Gao Jie³,Qiao Chenxi³,Tian Xiaolong³,Zhang Junping³,Demock Kellie⁴,Hao Ling-Yang⁴,Lesch Charles A.⁴,Morgan Rodney W.⁴,Moisan Jacques⁴,Wang Yahong⁴,Scatina JoAnn⁵,Paulos Chrystal M.⁶,Zou Weiping⁷,Carter Laura L.⁴,Hu Xiao⁴

Affiliation:

1. Department of Chemistry, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States

2. Chief Scientific Officer, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States

3. Department of Chemistry, Pharmaron Beijing, Co. Ltd., Beijing 100176, P. R. China

4. Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States

5. Department of Preclinical Development, Lycera Corp., 620 Germantown Pike, Plymouth Meeting, Pennsylvania 19462, United States

6. Hollings Cancer Center, Medical University of South Carolina, 173 Ashley Avenue, MSC 509, Room 203, Charleston, South Carolina 29425, United States

7. School of Medicine, Department of Surgery, University of Michigan, 2101 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00731

Reference104 articles.

1. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

3. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

4. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

5. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels;Antiviral Research;2024-01

2. Rational Design, Synthesis, and Anti-Proliferative Evaluation of Novel 4-Aryl-3,4-Dihydro-2H-1,4-Benzoxazines;Molecules;2023-12-27

3. Discovery of Biaryl Amide Derivatives as Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy;Journal of Medicinal Chemistry;2023-11-20

4. RORγT agonists as immune modulators in anticancer therapy.;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11

5. Chronic Glucocorticoid Exposure Induced an S1PR2-RORγ Axis to Enhance Hepatic Gluconeogenesis in Male Mice;Diabetes;2023-08-08